Brief: Eagle Pharmaceuticals Announces Licensing Agreement With Combioxin SA
25/08/2021 14:31
Aug 25 (Reuters) - Eagle Pharmaceuticals Inc EGRX.O :
* EAGLE PHARMACEUTICALS ANNOUNCES WORLDWIDE LICENSING
AGREEMENT
WITH COMBIOXIN SA FOR PHASE 2B/3, NOVEL FIRST-IN-CLASS ANTITOXIN
AGENT CAL02 IN DEVELOPMENT FOR COMBINATION USE WITH ANTIBIOTICS
FOR THE TREATMENT OF SEVERE PNEUMONIA
* EAGLE PHARMACEUTICALS INC - ANTICIPATES TEN YEARS OF
REGULATORY
EXCLUSIVITY
* EAGLE PHARMACEUTICALS INC - EAGLE EXPECTS TO INVEST $35
MILLION
TO ACHIEVE INTERIM RESULTS
* EAGLE PHARMACEUTICALS INC - INTERIM RESULTS ARE EXPECTED
IN
FIRST HALF OF 2023
* EAGLE PHARMACEUTICALS - WILL BE SOLELY RESPONSIBLE FOR
FURTHER
CLINICAL DEVELOPMENT OF CAL02 AND WILL MAKE AN UPFRONT PAYMENT
* EAGLE PHARMACEUTICALS INC - BELIEVES A CAL02 NEW DRUG
APPLICATION FOR TREATMENT OF SEVERE CABP MAY QUALIFY FOR
PRIORITY REVIEW
* EAGLE PHARMACEUTICALS - PLANS TO ADVANCE CLINICAL PROGRAM
AND
INITIATE A PHASE 2B/3 STUDY IN FIRST HALF OF 2022 FOR CAL02
Source text for Eikon: ID:nBw66tRV4a
Further company coverage: EGRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq